» Articles » PMID: 25819297

Immuno-evasive Tactics by Schistosomes Identify an Effective Allergy Preventative

Overview
Journal Exp Parasitol
Specialty Parasitology
Date 2015 Mar 31
PMID 25819297
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Many chronic inflammatory diseases can be improved by helminth infection, but the mechanisms are poorly understood. Allergy and helminthiasis are both associated with Th2-like immune responses; thus, defining how infection with parasites leads to reduced allergy has been particularly challenging. We sought to better understand this conundrum by evaluating host-parasite interactions involved in Th2 immunity in human schistosomiasis. Immune cells were cultured with schistosomes and the effect on CD23, an IgE receptor associated with resistance in schistosomiasis, was evaluated. Cells treated with schistosomes demonstrated reduced surface CD23 levels with a parallel accumulation of soluble (s) CD23 suggesting this IgE receptor is proteolytically cleaved by the parasite. Consistent with this hypothesis, a schistosome-generated (SG)-sCD23 fragment of 15 kDa was identified. SG-sCD23 inhibited IgE from binding to CD23 and FcεRI, but lacked the ability to bind CD21. These results suggested that schistosomes target IgE-mediated immunity in immuno-evasive tactics. Based on its characteristics, we predicted that SG-sCD23 would function as an efficacious allergy preventative. Treatment of human FcεRI-transgenic mice with recombinant (r) SG-sCD23 reduced the ability of human IgE to induce an acute allergic response in vivo. In addition, an optimized form of rSG-sCD23 with an introduced point mutation at Asp258 (D258E)to stabilize IgE binding had increased efficacy compared to native rSG-sCD23. Schistosome infection may thus inhibit allergic-like protective immune responses by increasing soluble IgE decoy receptors. Allergy treatments based on this naturally occurring phenomenon may be highly effective and have fewer side effects with long-term use.

Citing Articles

Clinical Use of Antigens as Novel Immunotherapies for Autoimmune Disorders.

Cleenewerk L, Garssen J, Hogenkamp A Front Immunol. 2020; 11:1821.

PMID: 32903582 PMC: 7438586. DOI: 10.3389/fimmu.2020.01821.


Immunomodulation by Helminths: Intracellular Pathways and Extracellular Vesicles.

Zakeri A, Hansen E, Andersen S, Williams A, Nejsum P Front Immunol. 2018; 9:2349.

PMID: 30369927 PMC: 6194161. DOI: 10.3389/fimmu.2018.02349.


Sm-p80-based schistosomiasis vaccine: double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy.

Zhang W, Molehin A, Rojo J, Sudduth J, Ganapathy P, Kim E Ann N Y Acad Sci. 2018; 1425(1):38-51.

PMID: 30133707 PMC: 6110104. DOI: 10.1111/nyas.13942.


CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells.

Selb R, Eckl-Dorna J, Neunkirchner A, Schmetterer K, Marth K, Gamper J J Allergy Clin Immunol. 2016; 139(1):290-299.e4.

PMID: 27372566 PMC: 5321593. DOI: 10.1016/j.jaci.2016.03.042.


Development of a schistosomiasis vaccine.

Molehin A, Rojo J, Siddiqui S, Gray S, Carter D, Siddiqui A Expert Rev Vaccines. 2015; 15(5):619-27.

PMID: 26651503 PMC: 5070536. DOI: 10.1586/14760584.2016.1131127.

References
1.
Punnonen J, Aversa G, Cocks B, De Vries J . Role of interleukin-4 and interleukin-13 in synthesis of IgE and expression of CD23 by human B cells. Allergy. 1994; 49(8):576-86. DOI: 10.1111/j.1398-9995.1994.tb00122.x. View

2.
Broide D . Immunomodulation of allergic disease. Annu Rev Med. 2009; 60:279-91. PMC: 2779001. DOI: 10.1146/annurev.med.60.041807.123524. View

3.
Hibbert R, Teriete P, Grundy G, Beavil R, Reljic R, Holers V . The structure of human CD23 and its interactions with IgE and CD21. J Exp Med. 2005; 202(6):751-60. PMC: 2212946. DOI: 10.1084/jem.20050811. View

4.
Fremeaux-Bacchi V, FISCHER E, Mani J, Bonnefoy J, Kazatchkine M . Soluble CD21 (sCD21) forms biologically active complexes with CD23: sCD21 is present in normal plasma as a complex with trimeric CD23 and inhibits soluble CD23-induced IgE synthesis by B cells. Int Immunol. 1998; 10(10):1459-66. DOI: 10.1093/intimm/10.10.1459. View

5.
Kelly A, Chen B, Woodward E, Conrad D . Production of a chimeric form of CD23 that is oligomeric and blocks IgE binding to the Fc epsilonRI. J Immunol. 1998; 161(12):6696-704. View